Related Experiment Video

Updated: Jun 1, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Managing multiple myeloma in the elderly: are we making progress?

Hang Quach1, H Miles Prince, Andrew Spencer

  • 1Department of Clinical Hematology, Faculty of Medicine, Nursing & Health Sciences, Monash University, Victoria, Australia. hang.quach@monash.edu

Expert Review of Hematology
|June 15, 2011
PubMed

Insights

Novel treatments for multiple myeloma improve survival, but benefits are less clear for elderly patients due to toxicities. Further research and careful application of therapies are needed for this group.

Area of Science:

  • Hematology
  • Geriatric Medicine
  • Oncology

Background:

  • Multiple myeloma treatment has advanced significantly with novel agents, improving overall survival.
  • However, survival benefits in elderly patients are less pronounced compared to younger individuals.
  • Treatment-related toxicities in older adults may offset the advantages of newer therapies.

Purpose of the Study:

  • To review the outcomes of elderly patients with multiple myeloma.
  • To focus on current treatment options for this specific patient subgroup.
  • To assess the impact of novel agents on elderly multiple myeloma patients.

Main Methods:

  • Review of recent literature and clinical data on elderly multiple myeloma patients.
  • Analysis of treatment outcomes, including survival and toxicity.
  • Focus on the efficacy and tolerability of novel therapeutic agents.

Main Results:

  • Novel agents have improved responses and salvage options for elderly patients.
  • The full survival impact of novel agents in the elderly is not yet fully understood due to limited data.
  • Treatment-related toxicities remain a significant concern in older populations.

Conclusions:

  • Progress is being made for elderly multiple myeloma patients through improved responses and salvage options.
  • Enhancing survival in elderly patients requires research into tolerable novel regimens and judicious use of current therapies.
  • Scrupulous supportive care and optimized dosing, combinations, and sequencing of novel agents are crucial.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...